

Osteoporosis Enrollment Form

| PATIENT INFORMATION: | Prescriber Information: |
|------------------------|-------------------------|
| Patient's Name: | Prescriber's Name: |
| Address: | DEA: |
| City, State, Zip Code: | NPI: |
| Home Phone: | Address: |
| Alternate Phone: | City, State, Zip Code: |
| DOB: | Phone: |
| Last 4 Digits of SS#: | Fax: |
| Gender: | Contact Person: |
| Language Preference: | Contact Person's Phone: |

INSURANCE INFORMATION: (please include copy of front and back of patient's prescription insurance card)

Prior Authorization Reference #: ____

| MEDICAL INFORMATION: (may attach separate sheet if needed) | | | | |
|--|--|--|--|--|
| Diagnosis: Please include diagnosis and ICD-10 code | Additional information: | | | |
| M80.00 Osteoporosis with current pathological fracture | Therapy: New Reauthorization Restart | | | |
| M81.00 Osteoporosis age-related with current | Weight: kg/lb Height cm/in BSA m ² | | | |
| pathological fracture | Allergies: | | | |
| M81.8 Other osteoporosis without current pathological | Fracture History: | | | |
| fracture | Prior Failed Therapies: 🗌 Risedronate 🗌 Ibandronate 🗌 Alendronate | | | |
| Other Diagnosis: | Prolia [®] (denosumab) Reclast [®] (zoledronic acid) | | | |
| ICD-10 Code: | Concomitant Medications: | | | |
| Description: | | | | |
| Disease State Description: | Injection Training Required: 🗌 Yes 🗌 No | | | |
| Postmenopausal osteoporosis with high fracture risk | | | | |
| Postmenopausal osteoporosis prophylaxis | Start Date End Date | | | |
| Hypogonadal osteoporosis with high fracture risk | | | | |
| Glucocorticoid-induced osteoporosis | Test Results: | | | |
| treatment/prophylaxis | Serum calcium | | | |
| Paget's disease | SCr/CrCl | | | |
| Other: | BMD | | | |
| Date of Diagnosis: | □ T score | | | |

| Prescription Information | | | | | |
|---|------------------|------------|----------|---------|--|
| Medication | Dose | Directions | Quantity | Refills | |
| Forteo® | 600mcg/2.4mL PFS | | | | |
| Prolia® | 60mg PFS | | | | |
| Reclast [®] | | | | | |
| Tymlos® | 80mcg Pen | | | | |
| OTHER: | | | | | |
| Please deliver to: Patient Office Other by this date: | | | | | |

Prescriber Authorization: I authorize this pharmacy and its representatives to act as my authorized agent to secure coverage and initiate the insurance prior authorization process for my patient(s), and to sign any necessary forms on my behalf as my authorized agent, including the receipt of any required prior authorization forms and the receipt and submission of patient lab values and other patient data. In the event that this pharmacy determines that it is unable to fulfill this prescription, I further authorize this pharmacy to forward this information and any related materials related to coverage of the product to another pharmacy of the patient's choice or in the patient's insurer's provider network.

Product Substitution Permitted Dispense as Written

Prescriber's Signature:

CONFIDENTIALITY STATEMENT: This communication is intended for the use of the individual or entity to which it is addressed and may contain information that is privileged, confidential, and exempt from disclosure under applicable law. If the reader of this communication is not the intended recipient or the employee or agent responsible for delivery of the communication, you are hereby notified that any dissemination, distribution, or copying of the communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone.